BACKGROUND: Neonatal diabetes mellitus (NDM) caused by mutations in KCNJ11 can be successfully treated with high dose oral sulfonylureas; however, little data is available on the risk of hypoglycemia. OBJECTIVE: To determine the frequency, severity, and clinical significance of hypoglycemia in KCNJ11-related NDM. METHODS: Utilizing the University of Chicago Monogenic Diabetes Registry, parents completed an online questionnaire addressing hypoglycemia. Continuous glucose monitoring (CGM) data was available for 7 subjects. RESULTS: Thirty subjects with KCNJ11-related permanent NDM (166 patient-years on sulfonylurea) had median sulfonylurea dose of 0.39 mg/kg/day (0.24-0.88 IQR, interquartile range) with median HbA1c 5.7% (39 mmol/mol) (5.5-6.1 IQR, 37-43 mmol/mol). Hypoglycemia (<70 mg/dL) was reported monthly once or less frequently in 89.3% of individuals, but 3 (10.7%) reported once weekly or more. Of all hypoglycemic episodes reported, none involved seizures or unconsciousness and thus did not meet the current ISPAD definition of severe hypoglycemia. Seven individuals wore a CGM for a total of 912 hours with blood sugars falling below 70 mg/dL for 5.8% of the time recorded, similar to ranges reported for people without diabetes. CONCLUSIONS: In our cohort of KCNJ11-related permanent NDM, hypoglycemia is infrequent and mild despite the high doses of sulfonylurea used and near-normal level of glycemic control. Long-term follow-up on larger numbers will be required to clarify the incidence and determinants of hypoglycemia in this unique population.
BACKGROUND:Neonatal diabetes mellitus (NDM) caused by mutations in KCNJ11 can be successfully treated with high dose oral sulfonylureas; however, little data is available on the risk of hypoglycemia. OBJECTIVE: To determine the frequency, severity, and clinical significance of hypoglycemia in KCNJ11-related NDM. METHODS: Utilizing the University of Chicago Monogenic Diabetes Registry, parents completed an online questionnaire addressing hypoglycemia. Continuous glucose monitoring (CGM) data was available for 7 subjects. RESULTS: Thirty subjects with KCNJ11-related permanent NDM (166 patient-years on sulfonylurea) had median sulfonylurea dose of 0.39 mg/kg/day (0.24-0.88 IQR, interquartile range) with median HbA1c 5.7% (39 mmol/mol) (5.5-6.1 IQR, 37-43 mmol/mol). Hypoglycemia (<70 mg/dL) was reported monthly once or less frequently in 89.3% of individuals, but 3 (10.7%) reported once weekly or more. Of all hypoglycemic episodes reported, none involved seizures or unconsciousness and thus did not meet the current ISPAD definition of severe hypoglycemia. Seven individuals wore a CGM for a total of 912 hours with blood sugars falling below 70 mg/dL for 5.8% of the time recorded, similar to ranges reported for people without diabetes. CONCLUSIONS: In our cohort of KCNJ11-related permanent NDM, hypoglycemia is infrequent and mild despite the high doses of sulfonylurea used and near-normal level of glycemic control. Long-term follow-up on larger numbers will be required to clarify the incidence and determinants of hypoglycemia in this unique population.
Authors: Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson Journal: J Diabetes Sci Technol Date: 2011-07-01
Authors: Wojciech Mlynarski; Andrei I Tarasov; Agnieszka Gach; Christophe A Girard; Iwona Pietrzak; Lejla Zubcevic; Jacek Kusmierek; Tomasz Klupa; Maciej T Malecki; Frances M Ashcroft Journal: Nat Clin Pract Neurol Date: 2007-11
Authors: Roger S Mazze; Ellie Strock; David Wesley; Sarah Borgman; Blaine Morgan; Richard Bergenstal; Robert Cuddihy Journal: Diabetes Technol Ther Date: 2008-06 Impact factor: 6.118
Authors: Andrey P Babenko; Michel Polak; Hélène Cavé; Kanetee Busiah; Paul Czernichow; Raphael Scharfmann; Joseph Bryan; Lydia Aguilar-Bryan; Martine Vaxillaire; Philippe Froguel Journal: N Engl J Med Date: 2006-08-03 Impact factor: 91.245
Authors: D Iafusco; O Massa; B Pasquino; C Colombo; L Iughetti; C Bizzarri; C Mammì; D Lo Presti; T Suprani; R Schiaffini; Colin G Nichols; L Russo; V Grasso; F Meschi; R Bonfanti; S Brescianini; F Barbetti Journal: Acta Diabetol Date: 2011-09-28 Impact factor: 4.280
Authors: Nelly Mauras; Roy Beck; Dongyuan Xing; Katrina Ruedy; Bruce Buckingham; Michael Tansey; Neil H White; Stuart A Weinzimer; William Tamborlane; Craig Kollman Journal: Diabetes Care Date: 2011-12-30 Impact factor: 19.112
Authors: Elisa De Franco; Cécile Saint-Martin; Klaus Brusgaard; Amy E Knight Johnson; Lydia Aguilar-Bryan; Pamela Bowman; Jean-Baptiste Arnoux; Annette Rønholt Larsen; May Sanyoura; Siri Atma W Greeley; Raúl Calzada-León; Bradley Harman; Jayne A L Houghton; Elisa Nishimura-Meguro; Thomas W Laver; Sian Ellard; Daniela Del Gaudio; Henrik Thybo Christesen; Christine Bellanné-Chantelot; Sarah E Flanagan Journal: Hum Mutat Date: 2020-02-17 Impact factor: 4.878
Authors: Matthew C Riddle; Louis H Philipson; Stephen S Rich; Annelie Carlsson; Paul W Franks; Siri Atma W Greeley; John J Nolan; Ewan R Pearson; Philip S Zeitler; Andrew T Hattersley Journal: Diabetes Care Date: 2020-12 Impact factor: 19.112
Authors: Pamela Bowman; Timothy J McDonald; Bridget A Knight; Sarah E Flanagan; Maria Leveridge; Steve R Spaull; Beverley M Shields; Suzanne Hammersley; Maggie H Shepherd; Robert C Andrews; Kashyap A Patel; Andrew T Hattersley Journal: BMJ Open Diabetes Res Care Date: 2019-12-18